Linfeng Xu

680 citations
24 papers · 251 indexed · h-index 10
Topics
Hepatocellular Carcinoma Treatment and Prognosis (12 papers)Cholangiocarcinoma and Gallbladder Cancer Studies (6 papers)Cancer Mechanisms and Therapy (4 papers)
Journals
SHILAP Revista de lepidopterologíaOncogeneThe Plant Journal
Partner nations
ChinaUnited States

In The Last Decade

Linfeng Xu

20 papers receiving 250 citations

Peers

Linfeng Xu
Comparison fields: 5 of 42
  • Hepatology 128
  • Molecular Biology 73
  • Cancer Research 64
  • Epidemiology 63
  • Pulmonary and Respiratory Medicine 57
Replace Yutaro Mihara with:
Yutaro Mihara Japan
Satoshi Moriya Japan
Yichuan Yuan China
Loretta D’Onofrio Italy
Mengxian Tu China
Kazuki Maesaka Japan
Ziyu Xun China
Renfeng Shan China
Ningyuan Wen China
Linfeng Xu relative to Yutaro Mihara Japan Yutaro Mihara's profile →
Citations per field
00.5×6.5×
Yutaro Mihara · 1×
Citations per year

Countries citing papers authored by Linfeng Xu

Since Specialization
Citations

This map shows the geographic impact of Linfeng Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Linfeng Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Linfeng Xu more than expected).

Fields of papers citing papers by Linfeng Xu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Linfeng Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Linfeng Xu. The network helps show where Linfeng Xu may publish in the future.

Co-authorship network of co-authors of Linfeng Xu

This figure shows the co-authorship network connecting the top 25 collaborators of Linfeng Xu. A scholar is included among the top collaborators of Linfeng Xu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Linfeng Xu. Linfeng Xu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 0
2 0
3 2
4 1
5 5
6 5
7 10
8 54
9 9
10 9
11 10
12 13
13 7
14 3
15 9
16 1
17 6
18 17
19 33
20 39

About Linfeng Xu

Linfeng Xu is a scholar working on Hepatology, Pathology and Forensic Medicine and Cancer Research, having authored 24 papers that have together received 251 indexed citations. Recurring topics across this work include Hepatocellular Carcinoma Treatment and Prognosis (12 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (6 papers) and Cancer Mechanisms and Therapy (4 papers). The work is most often cited by research in Hepatology (128 citations), Cancer Research (64 citations) and Pathology and Forensic Medicine (39 citations). Linfeng Xu has collaborated with scholars based in China and United States. Frequent co-authors include Jiayan Ni, Hongliang Sun, Jianghong Luo, Xiongying Jiang, Shanshan Liu, Weidong Wang, Jingxing Zhou, Binhui Xie, Long Shen and Jie Hu. Their work appears in journals such as SHILAP Revista de lepidopterología, Oncogene and The Plant Journal.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026